In response to the United States Supreme Court’s decision in the Students for Fair Admissions v. University of North Carolina and Students for Fair Admissions v Harvard cases, the ATA remains committed to diversity, equity, and inclusion. Health care and the science of medicine benefit greatly from race-conscious diversity and we will continue to strive to represent our patients and our members to advance research, clinical care, and diminish inequities in the treatment of thyroid diseases.
Promoting diversity in healthcare allows for a broader range of perspectives, experiences, and expertise, which can lead to better patient care outcomes. Different racial and ethnic backgrounds can influence how diseases manifest, respond to treatments, and affect patients’ overall health.
The ATA’s dedication to promoting diversity and reducing inequities in the treatment of thyroid diseases aligns with the broader goals of improving healthcare and ensuring equal access to quality care for all individuals. By promoting inclusivity and equity, the ATA is committed to helping ensure that all individuals, regardless of their background, receive fair and effective treatment for thyroid diseases.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.